阿托伐他汀强化降脂治疗对急性冠脉综合征患者血清炎症因子的影响

目的：探讨阿托伐他汀强化降脂对急性冠脉综合征（ACS）患者血清高敏C-反应蛋白（hs-CRP）的影响及其对ACS炎症抑制和斑块稳定的作用。方法：80例ACS患者随机分为两组各40例,常规治疗组予常规药物治疗,但不用降脂药物;阿托伐他汀组在常规治疗的基础上予阿托伐他汀40mg/d,口服疗程2个月。治疗后7天及30天抽取静脉血检测血清hs-CRP水平。结果：治疗后7天,阿托伐他汀组血清hs-CRP水平较治疗前明显降低（P〈0.05）,而常规治疗组无明显变化;治疗后30天,常规治疗组血清hs-CRP水平降至正常,而阿托伐他汀组血清hs-CRP水平降低程度较常规治疗组更为明显（P〈0.05）。结论：阿托伐他汀能降低ACS患者的血清炎症因子,具有抑制炎症和稳定斑块作用。

Intensive lipid-lowering effect of atorvastatin treatment in patients with acute coronary

Objective：To explore the use of intensive lipid-lowering effect of atorvastatin in patients with acute coronary syndrome,serum high-sensitivity C-reactive protein（hs-CRP）the impact of ACS in order to understand their effects on inhibiting inflammation and plaque stability.Methods：80 patients selected ACS patients were randomly divided into conventional therapy group（n=40）and the atorvastatin group（n=40）.Conventional treatment group received conventional drug therapy,without lipid-lowering drug atorvastatin group was atorvastatin 40 mg/d,orally.Drug therapy in all patients before and after treatment 7d and 30d collected blood examination hs-CRP.Results：The atorvastatin group after treatment 7d serum hs-CRP levels were significantly lower（P0.05）,whereas no significant change in the conventional group.The conventional therapy group after 30d of serum hs-CRP to normal levels,but lower atorvastatin group was significantly higher than the conventional therapy group level（P0.05）.Conclusions：Atorvastatin could reduce inflammatory factors in serum of patients with ACS with a role in inhibiting inflammation and plaque stability.